Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.

Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.

JTO Clin Res Rep   2023.10

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, Tambo, Sonoda T, Miya

Cancer Chemother Pharmacol   2023.7

Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study.

Takata S, Morikawa K, Tanaka H, Itani H, Ishihara M, Horiuchi K, Kato Y, Ikemura S, Nakagawa H, Nakahara Y, Seki Y, Bessho A, Takahashi N, Hayashi K, Endo T, Takeyama K, Maekura T, Takigawa N, Kawase A, Endoh M, Nemoto K, Kishi K, Soejima K, Okuma Y, Yoshimura K, Saigusa D, Kanai Y, Ueda K, Togashi A, Matsutani N, Seki N.

Ther Adv Med Oncol   2023.6

Hokkaido Lung Cancer Clinical Study Group Trial. Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.

Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H

Cancer Med.   2023.5

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: A prospective pilot study.

Makiguchi T, Tanaka H, Okudera K, Taima K, Tasaka S.

Transl Lung Cancer Res.   2023.4

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med.   62 ( 4 )   589 - 593   2023.2

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med.   2023.2

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility

Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H.

JAMA Netw Open   6 ( 2 )   2023.2

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)

Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer.   14 ( 2 )   2023.1

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N.

Ther Adv Med Oncol.   14   2022.12

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series.

Ishioka Y, Makiguchi T, Itoga M, Tanaka H, Taima K, Goto S, Tasaka S

Chest   162 ( 6 )   e311 - e316   2022.12

A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630

28 ( 20 )   4402 - 4409   2022.10

クライオバイオプシーで診断した肺クリプトコックス症の1例．

小田切 遥, 牧口 友紀, 福島 高志, 石岡 佳子, 糸賀 正道, 田中 寿志, 當麻 景章, 田坂 定智．

気管支学（日本呼吸器内視鏡学会雑誌)   44 ( 5 )   325 - 330   2022.9

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.

Fukushima T, Makiguchi T, Tanaka Y, Chubachi K, Ishidoya M, Suzuki S, Tanaka H, Taima K, Hasegawa Y, Okudera K, Tasaka S.

Oncol Lett.   24 ( 4 )   368   2022.9

HER2遺伝子変異陽性肺癌に対して化学放射線療法後にデュルバルマブを投与した1例．

佐々木悠子，田中寿志，牧口友紀，小堀由璃，小田切遥，田坂定智．

日本呼吸器学会誌   11(5)   310 - 314   2022.9

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia.

Tabe C, Dobashi M, Ishioka Y, Itoga M, Tanaka H, Taima K, Tasaka S.

BMC Res Notes   15   263   2022.7

Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.

Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S.

2022.6

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).

Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer.   2022.5

Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.

Makiguchi T, Tanaka H, Taima K, Takayasu S, Tasaka S

Thorac Cancer   13 ( 8 )   1220 - 1223   2022.4

Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report

2022.2

Bilateral Thalamic Lesions Associated With Atezolizumab-Induced Encephalitis: A Follow-up Report With Autopsy Findings.

Nishijima H, Kon T, Seino Y, Yagihashi N, Suzuki C, Nakamura T, Tanaka H, Sakamoto Y, Wakabayashi K, Tomiyama M

Neurology   98 ( 5 )   204 - 205   2022.2

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.

Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi

Cancers   14 ( 2 )   2022.1

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

Mimori T, Shukuya T, Ko , Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K

Cancers (Basel)   2022.1

Ⅲ各種抗がん薬　22-17.　MET阻害薬

田中寿志

新臨床腫瘍学（改訂第7版）   2022

肺癌診療ガイドライン

田中寿志

肺癌診療ガイドライン2022年度版   2022

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).

Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe

Scientific reports   11 ( 1 )   23140 - 23140   2021.11

Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.

Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S

Thoracic cancer   12 ( 20 )   2811 - 2814   2021.10

Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.

Tomonori Makiguchi, Hisashi Tanaka, Kosuke Kamata, Kageaki Taima, Akira Kurose, Sadatomo Tasaka

Thoracic cancer   12 ( 20 )   2811 - 2814   2021.8

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients

2021.7

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.

Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S.

JCSM Clin Rep   2021.7

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.

Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S

JCSM Clinical Reports   6   103 - 108   2021.7

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa

Thoracic cancer   12 ( 14 )   2113 - 2121   2021.6

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).

Shotaro Ito, Hajime Asahina, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Satoshi Oizumi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka-Akita, Hiroshi Isobe

Lung cancer (Amsterdam, Netherlands)   156   12 - 19   2021.6

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung.

Masamichi Itoga, Hisashi Tanaka, Kageaki Taima, Yoshiko Ishioka, Hiroaki Sakamoto, Shingo Takanashi, Akira Kurose, Sadatomo Tasaka

BMC research notes   14 ( 1 )   25 - 25   2021.1

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.

Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka

Cancer communications (London, England)   41 ( 1 )   83 - 87   2021.1

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.

Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka

Cancer communications (London, England)   41 ( 1 )   83 - 87   2021.1

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.

Masaki Dobashi, Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Toshihiro Shiratori, Fumihiko Okumura, Chiori Tabe, Yoshihito Tanaka, Takeshi Morimoto, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka

SAGE open medicine   9   20503121211023357 - 20503121211023357   2021

日本臨床　領域別症候群シリーズ　腫瘍性疾患　「Pancoast症候群」

田中　寿志、田坂　定智

肺癌診療ガイドライン　2021年度版   2021

A Phase I/II study of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer.

Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, Ishioka Y, Itoga M, Taima K, Yokouchi J, Hatayama Y, Aoki M, Tasaka S.

Clin Lung Cancer   22(1)   42 - 48   2021

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study).

Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Saori Takata, Satoshi Watanabe, Kazuma Kishi, Kenzo Soejima, Kyoichi Kaira, Hiroshi Kagamu, Kenichi Yoshimura, Noriyuki Matsutani, Nobuhiko Seki

Therapeutic advances in medical oncology   12   1758835920967254 - 1758835920967254   2020.10

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).

Atsushi Nakamura, Hisashi Tanaka, Ryota Saito, Aya Suzuki, Toshiyuki Harada, Sumito Inoue, Toru Yamada, Taku Nakagawa, Daisuke Jingu, Shunichi Sugawara

The oncologist   25 ( 10 )   e1451 - e1456   2020.10

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.

Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka

Clinical lung cancer   22 ( 1 )   42 - 48   2020.10

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.

Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka

Clinical lung cancer   22 ( 1 )   42 - 48   2020.10

Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.

Toshihiro Shiratori, Hisashi Tanaka, Chiori Tabe, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Shingo Takanashi, Sadatomo Tasaka

Thoracic cancer   11 ( 6 )   1720 - 1723   2020.6

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab.

Kageaki Taima, Hisashi Tanaka, Masamichi Itoga, Yoshiko Ishioka, Akira Kurose, Sadatomo Tasaka

Respirology case reports   8 ( 5 )   e00580 - e00580   2020.5

A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer

Tanaka H, Tabe C, Okumura F, Shiratori T, Ishioka Y, Itoga M, Taima K, Morimoto T, Kimura D, Tsushima T, Tasaka S.

Thorac Cancer   11   1633 - 1638   2020.4

Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)

Ariyasu Ryo, Tambo Yuichi, Tanimoto Azusa, Sonoda Tomoaki, Koyama Junji, Uenami Takeshi, Kudo Keita, Tsuchiya Yuko, Nishio Makoto, Uchibori Ken, Tanaka Hisashi, Miyauchi Eisaku, Kawashima Yosuke, Ohyanagi Fumiyoshi, Horiike Atsushi, Sakatani Toshio, Saiki Masafumi

Haigan   60 ( 7 )   966 - 971   2020

The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.

Hiroaki Sakamoto, Hisashi Tanaka, Toshihiro Shiratori, Keisuke Baba, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka

Molecular and clinical oncology   10 ( 6 )   610 - 614   2019.6

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.

Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Keisuke Baba, Toshihiro Shiratori, Hiroaki Sakamoto, Junichiro Tsuchiya, Hideyuki Nakagawa, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka

Medical oncology (Northwood, London, England)   36 ( 6 )   57 - 57   2019.5

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka

Thoracic cancer   10 ( 2 )   369 - 372   2019.2

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki

Thoracic cancer   10 ( 2 )   395 - 400   2019.2

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Baba K, Tanaka H, Sakamoto H, Shiratori T, Tsuchiya J, Ishioka Y, Itoga M, Taima K, Tasaka S

Thorac Cancer   2019.1

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ryo Ko, Takehito Shukuya, Yusuke Okuma, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Satoshi Morita, Kunihiko Kobayashi, Toshihiro Nukiwa, Kazuhisa Takahashi,

The oncologist   23 ( 10 )   1210 - 1217   2018.10

脊髄炎，感覚性軸索型ニューロパチーを呈した傍腫瘍性神経症候群の1例

土屋純一郎，田中　寿志，當麻　景章　他

日本呼吸器学会誌   7 ( 4 )   212 - 215   2018.7

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga, Yoshiko Ishioka, Hideyuki Nakagawa, Keisuke Baba, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka

Medical oncology (Northwood, London, England)   35 ( 3 )   34 - 34   2018.2

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.

Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka

BMC cancer   17 ( 1 )   683 - 683   2017.10

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.

Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Kunihiko Nakamura, Yoshihito Tanaka, Masamichi Itoga, Shingo Takanashi, Ken Okumura

BMC research notes   9 ( 1 )   173 - 173   2016.3

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, Ryota Saito, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Takeshi Horai, Makoto Nishio

Anti-cancer drugs   26 ( 5 )   573 - 578   2015.6

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus.

Masamichi Itoga, Yuko Asari, Takeshi Morimoto, Kageaki Taima, Kunihiko Nakamura, Yoshihito Tanaka, Hisashi Tanaka, Shingo Takanashi, Hiroyuki Kayaba, Ken Okumura

BMC research notes   8   268 - 268   2015.6

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takeshi Horai, Makoto Nishio

Anticancer research   34 ( 4 )   1975 - 1981   2014.4

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.

Hisashi Tanaka, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Kunihiko Nakamura, Akihito Hayashi, Akira Kurose, Ken Okumura, Shingo Takanashi

OncoTargets and therapy   7   87 - 90   2013.12

Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.

Hisashi Tanaka, Kiyoshi Tone, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Hideyuki Nakagawa, Shingo Takanashi, Ken Okumura, Akira Kurose

Lung cancer (Amsterdam, Netherlands)   80 ( 3 )   289 - 292   2013.6

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura

BMC cancer   12   558 - 558   2012.11